Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Respiratory Insufficiency 1Radiation Pneumonitis 1Neuroendocrine Tumors 1Lung Neoplasms 1Lung Diseases 1Abnormalities, Radiation-Induced 1

Interventions

lutetium Lu 177 dotatate 21Magnetic Resonance Spectroscopy 10pembrolizumab 9Specimen Handling 7Everolimus 7cabozantinib 6Nivolumab 6lenvatinib 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5surufatinib 4olaparib 4amino-acid, glucose, and electrolyte solution 4lanreotide 3atezolizumab 3Temozolomide 3Octreotide 3Lutetium-177 3Ipilimumab 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2X-Rays 2Radiotherapy 2Phantoms, Imaging 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Tomography, Emission-Computed, Single-Photon × 1 year × Clear all
NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
10 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡